(NEO: MMED)MindMed (OTCQB: MMEDF) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together..
Share this article
Share this article
ZUG, Switzerland, Feb. 11, 2021 /PRNewswire/ MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.
As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have already been synthesized by MindShift Compounds AG and related patent applications were filed by MindMed. MindMed plans to begin first-in-human Phase 1 clinical trials as early as Q1 2022 through its existing clinical trial platform for psychedelic and empathogenic compounds in Switzerland.
Operator
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. [Operator Instructions] I will now hand the conference call over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, sir.
Vincent Anzalone
Vice President, Head of Investor Relations
Thanks, Aldan. Good afternoon, everyone. Thank you for joining us today to discuss Arrowhead s results for its fiscal 2021 first quarter ended December 31, 2020. With us today from management are President and CEO, Dr. Christopher Anzalone; who will provide an overview of the quarter; Dr. James Hamilton, our Senior Vice President of Discovery and Translational Medicine, who has graciously agreed to sub in for Dr. Javier San Martin while he is out ill today; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. In addition, James Hassard, our Chief Commercial Officer, will be available during the Q&A portion of today s call.
Share this article
Share this article
NEW YORK, Feb. 5, 2021 /PRNewswire/ The Galien Foundation announced today an upcoming webinar series that will explore the critical role digital technologies play in today s life sciences, specifically in clinical trials and the development of the COVID-19 vaccines.
(PRNewsfoto/The Galien Foundation)
On Wednesday, February 17, 2021 at 12:00pm-1:00pm EST, The Galien Foundation will host the first session, The Impact of Digital Technologies in Transforming and Accelerating Vaccine Trials, Development and Delivery: Lessons from COVID-19. Moderated by Jessica Federer, Managing Director, Huma, Former Chief Digital Officer, Bayer, the panel includes Rachel Berria, MD, PhD, Vice President and Medical Head, US Biopharmaceuticals AstraZeneca; Marie-Pierre Hellio Le Graverand, MD, DSc, PhD, SVP, Head of Clinical Development and Operations, Pfizer; Terry Murphy, COVID-19 Clinical Development Relaunch Leader, VP, Global Head Enabling Business Infor
SIFI Announces the Publication of its Phase I Study on Polihexanide in the British Journal of Ophthalmology
01/02/2021 - 12:50 );
Polihexanide 0.08% Exhibits Compelling Safety and Tolerability Characteristics in Healthy Volunteers
CATANIA, Italy, Feb. 1, 2021 /PRNewswire/ SIFI, a leading ophthalmic company, announced today the publication of clinical results from its Phase I trial of polihexanide in healthy volunteers. The paper was published as on-line first in the peer-reviewed journal British Journal of Ophthalmology. The main objective of the study was to evaluate the safety and tolerability of increasing doses of polihexanide eye drops in order to choose a dose that would be tested in the phase III clinical trial in patients with Acanthamoeba Keratitis (AK). Results of the trial showed a good safety and tolerability profile including the 0.08% dose, the highest tested.